We are live on ! Find out more
SLXNW

Silexion Therapeutics Warrant
SLXNW

22 hedge funds and large institutions have $108K invested in Silexion Therapeutics Warrant in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

21.01% more ownership

Funds ownership: 23.82% → 44.83% (+21%)

12% less funds holding

Funds holding: 25 → 22 (-3)

46% less capital invested

Capital invested by funds: $199K → $108K (-$91.5K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
22
Holders Change
-3
Holders Change %
-12%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
2
Closed
3
Calls
$173K
Puts
–
Net Calls
+$173K
Net Calls Change
+$156K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$5.26K
2
CS
Clear Street
New York
+$3.95K
3
Goldman Sachs
Goldman Sachs
New York
+$184

Top Sellers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
-$6.67K
2
YCM
Yakira Capital Management
Connecticut
-$5.74K
3
RCM
Rivernorth Capital Management
Florida
-$1.15K
4
Jane Street
Jane Street
New York
-$21
5
Bank of America
Bank of America
North Carolina
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
1
Polar Asset Management Partners
Ontario, Canada
$30.4K – – –
LA
2
Linden Advisors
New York
$14K – – –
AC
3
Aristeia Capital
Connecticut
$9.78K – – –
CS
4
Clear Street
New York
$8.99K +$3.95K +74,600 +51%
HP
5
Hartree Partners
New York
$7.29K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$5.75K +$5.26K +99,181 +191%
SBLIC
7
Security Benefit Life Insurance Company
Kansas
$5.71K – – –
Goldman Sachs
8
Goldman Sachs
New York
$4.64K +$184 +3,476 +3%
KC
9
Kepos Capital
New York
$4K – – –
Jane Street
10
Jane Street
New York
$3.06K -$21 -392 -0.5%
CCM
11
Context Capital Management
California
$2.09K – – –
TCM
12
Tenor Capital Management
New York
$2.04K – – –
PMAM
13
Picton Mahoney Asset Management
Ontario, Canada
$2K – – –
GCIA
14
Gabelli & Co Investment Advisers
New York
$1.56K – – –
Neuberger Berman Group
15
Neuberger Berman Group
New York
$1.29K – – –
GF
16
Gabelli Funds
New York
$1.25K – – –
DCM
17
Dupont Capital Management
Delaware
$1.24K – – –
MTCM
18
Mint Tower Capital Management
Netherlands
$1K – – –
Stifel Financial
19
Stifel Financial
Missouri
$654 – – –
SCM
20
Saba Capital Management
New York
$488 – – –
CCA
21
Cobblestone Capital Advisors
New York
$409 – – –
Bank of America
22
Bank of America
North Carolina
$4 -$1 -10 -9%
PC
23
Periscope Capital
Ontario, Canada
– -$6.67K -87,169 Closed
YCM
24
Yakira Capital Management
Connecticut
– -$5.74K -75,000 Closed
RCM
25
Rivernorth Capital Management
Florida
– -$1.15K -14,999 Closed

SLXNW Hedge Fund Activity: Q2 2025 in Review

22 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q2 2025, worth a combined $108K — down 46% from $199K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SLXNW and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, adding an estimated $5.26K. The largest seller was Periscope Capital, exiting entirely with an estimated $6.67K sold.

  • 22 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q2 2025, down from 25 in Q1 2025.
  • Funds reported $108K of Silexion Therapeutics Warrant stock for Q2 2025, down 46% quarter-over-quarter.
  • 0 funds opened new Silexion Therapeutics Warrant positions in Q2 2025 and 3 closed out, a net change of -3 holders.
  • The largest Silexion Therapeutics Warrant buyer in Q2 2025 was Susquehanna International Group, an estimated $5.26K added.
  • The largest Silexion Therapeutics Warrant seller in Q2 2025 was Periscope Capital, an estimated $6.67K sold.

Based on aggregated 13F filings for Q2 2025.